{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:25:00Z","timestamp":1786926300188,"version":"build-2736575974"},"reference-count":7,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Emerging modalities in drug development including adeno-associated virus (AAV) and other viral-mediated gene therapy, targeted protein degraders, oligonucleotide, and chimeric antigen receptor-T cell (CAR-T) therapies require updated approaches in strategy and context for meaningful human carcinogenicity risk assessment. This may involve, but is not be limited to, traditional genetic toxicology and rodent bioassays. Speakers provided unique perspectives on these topics as well as an applicable and real-world case study that interrogated whether rat mammary gland cell proliferation was a useful tool with which to evaluate the carcinogenic potential of exogenous insulin.<\/jats:p>","DOI":"10.1177\/01926233261453045","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T18:02:06Z","timestamp":1782237726000},"page":"370-373","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["New Modalities and Carcinogenicity Assessment"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-6661","authenticated-orcid":false,"given":"Emily K.","family":"Meseck","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Inc, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7808-3462","authenticated-orcid":false,"given":"Paul","family":"Batty","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8757-2790","authenticated-orcid":false,"given":"Tae-Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"M\u00f8lck","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Maaloev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi Flou Hjorth","family":"Jensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Maaloev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5402-896X","authenticated-orcid":false,"given":"James","family":"Sidaway","sequence":"additional","affiliation":[{"name":"ApconiX, Alderley Edge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8803-1412","authenticated-orcid":false,"given":"Ronnie","family":"Chamanza","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine, High Wycombe, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Maria","family":"Dalsgaard","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Maaloev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-7262","authenticated-orcid":false,"given":"Dirk","family":"Schaudien","sequence":"additional","affiliation":[{"name":"Fraunhofer ITEM, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-2745","authenticated-orcid":false,"given":"Sandra","family":"De Jonghe","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Innovative Medicine, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7104-4612","authenticated-orcid":false,"given":"Barbara","family":"Lenz","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-0146","authenticated-orcid":false,"given":"Thomas","family":"Nolte","sequence":"additional","affiliation":[{"name":"NonClinical Safety and DMPK, Boehringer-Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. Committee for Proprietary Medicinal Products (CPMP) points to consider document on the non-clinical assessment of the carcinogenic potential of insulin ANA. 2001. Accessed April 30 2026. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/points-consider-document-non-clinical-assessment-carcinogenic-potential-insulin-analogues_en.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251406537"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103643"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0079710"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/1091581820941776"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/D41573-022-00055-9"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00585995"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01926233261453045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/01926233261453045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01926233261453045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:46:32Z","timestamp":1786923992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/01926233261453045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/01926233261453045"],"URL":"https:\/\/doi.org\/10.1177\/01926233261453045","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}